Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Press Release|Articles|January 29, 2025
Camber Pharmaceuticals Announces Addition of Sirolimus Oral Solution
Key Takeaways
- Sirolimus Oral Solution is indicated for organ rejection prophylaxis in renal transplant patients aged 13 and older.
- Low to moderate risk patients should initially use it with CsA and corticosteroids, withdrawing CsA 2 to 4 months post-transplant.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Sirolimus Oral Solution.
Sirolimus Oral Solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged greater or equal to 13 years receiving renal transplants.
- Patients at low to moderate immunologic risk: use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2 to 4 months after transplantation.
- Patients at high immunologic risk: use in combination with CsA and corticosteroids
Sirolimus Oral Solution 1 mg/mL is now available in a 60 mL bottle.
To find out more information on Sirolimus Oral Solution, please visit:
Advertisement
Related to this article
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5